ALK and non-small cell lung carcinoma: Compared with NSCLC patients with stage IV, ALK rearrangements were underrepresented in NSCLC patients with stage I–III (OR = 0.58; 95% CI: 0.44–0.78; P = 0.0002), without heterogeneity (I2 = 2%).